RWD-Cockpit: Application for quality assessment of real-world data
ABSTRACT: Digital technologies are transforming the healthcare system. A large part of information is generated as real-world data (RWD). Data from electronic health records and digital biomarkers have the potential to reveal associations between the benefits and adverse events of medicines, establish new patient stratification principles, expose unknown disease correlations, and inform on preventive measures. The impact for healthcare payors and providers, the biopharmaceutical industry and governments, is massive in terms of health outcomes, quality of care and cost. However, a framework to assess preliminary quality of RWD is missing, thus hindering the conduct of population-based observational studies to support regulatory decision-making and real-world evidence (RWE).
RWD-Cockpit: Application for quality assessment of real-world data
ABSTRACT: Digital technologies are transforming the healthcare system. A large part of information is generated as real-world data (RWD). Data from electronic health records and digital biomarkers have the potential to reveal associations between the benefits and adverse events of medicines, establish new patient stratification principles, expose unknown disease correlations, and inform on preventive measures. The impact for healthcare payors and providers, the biopharmaceutical industry and governments, is massive in terms of health outcomes, quality of care and cost. However, a framework to assess preliminary quality of RWD is missing, thus hindering the conduct of population-based observational studies to support regulatory decision-making and real-world evidence (RWE).
RWD-Cockpit: Application for quality assessment of real-world data
Babrak L, Smakaj E, Agac T, Asprion P, Grimberg F, Van der Werf D, van Ginkel E, Tosoni D, Clay I, Degan M, Brodbeck D, Natali E, Schkommodau E, MIho E
ABSTRACT: Digital technologies are transforming the healthcare system. A large part of information is generated as real-world data (RWD). Data from electronic health records and digital biomarkers have the potential to reveal associations between the benefits and adverse events of medicines, establish new patient stratification principles, expose unknown disease correlations, and inform on preventive measures. The impact for healthcare payors and providers, the biopharmaceutical industry and governments, is massive in terms of health outcomes, quality of care and cost. However, a framework to assess preliminary quality of RWD is missing, thus hindering the conduct of population-based observational studies to support regulatory decision-making and real-world evidence (RWE).
RWD-Cockpit: Application for quality assessment of real-world data
Evidation and the Duke Big Ideas Lab have announced a partnership that aims to find ways to both increase representation of underserved populations and improve adherence among all participants in digital health studies.
The organizations are working together to build an analytic structure that will be available to other digital health researchers, helping to better predict study participation, adherence, and retention. Click below to read more about the project, led by Iredia M. Olaye, PhD, MSc, MHA, of Covered By Group and Evidation, in HealthLeaders.
Thanks to everyone who took the time to meet with us in San Francisco at this year’s J.P. Morgan Annual Conference and its surrounding events. Our team looks forward to staying in touch and helping you produce better health outcomes in 2023!
Get to know your Evidation team
Bertina Yen, Evidation's Senior Vice President of People & Community
Bertina Yen is Evidation's Senior Vice President of People & Community, where she is responsible for the end-to-end employee experience and building a community that supports everyone's ability to show up as their authentic selves and perform their best work. Prior to joining Evidation, Bertina served as EVP overseeing clinical teams, product management, marketing, and product development at Zynx Health, driving development of evidence-based clinical decision support solutions that improve health and financial outcomes.
Bertina received her BAS from Stanford, then completed her MD and residency in internal medicine at UC San Diego. She also holds an MPH in health services administration from UCLA.
Bertina is the resident DJ at Evidation and sources the music that is played during the All-Employee Meetings. Outside of work, she enjoys hiking, traveling, and watching anything with a live audience (sporting events, plays, movies). She also starts every morning by completing at least one crossword puzzle!
RWD-Cockpit: Application for quality assessment of real-world data
ABSTRACT: Digital technologies are transforming the healthcare system. A large part of information is generated as real-world data (RWD). Data from electronic health records and digital biomarkers have the potential to reveal associations between the benefits and adverse events of medicines, establish new patient stratification principles, expose unknown disease correlations, and inform on preventive measures. The impact for healthcare payors and providers, the biopharmaceutical industry and governments, is massive in terms of health outcomes, quality of care and cost. However, a framework to assess preliminary quality of RWD is missing, thus hindering the conduct of population-based observational studies to support regulatory decision-making and real-world evidence (RWE).
RWD-Cockpit: Application for quality assessment of real-world data
Babrak L, Smakaj E, Agac T, Asprion P, Grimberg F, Van der Werf D, van Ginkel E, Tosoni D, Clay I, Degan M, Brodbeck D, Natali E, Schkommodau E, MIho E
ABSTRACT: Digital technologies are transforming the healthcare system. A large part of information is generated as real-world data (RWD). Data from electronic health records and digital biomarkers have the potential to reveal associations between the benefits and adverse events of medicines, establish new patient stratification principles, expose unknown disease correlations, and inform on preventive measures. The impact for healthcare payors and providers, the biopharmaceutical industry and governments, is massive in terms of health outcomes, quality of care and cost. However, a framework to assess preliminary quality of RWD is missing, thus hindering the conduct of population-based observational studies to support regulatory decision-making and real-world evidence (RWE).
